Patient preferences for oral versus intravenous adjuvant chemotherapy for early breast cancer

Patient preferences for oral versus intravenous adjuvant chemotherapy for early breast cancer - Patient preferences for chemotherapy for early breast cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000004696

Enrollment

200

Registered

2010-12-10

Start date

2010-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early breast cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) Postmenopausal women with stage I to III breast cancer at diagnosis 2) HER2 negative 3) ER and/or PgR positive 4) Already finished her adjuvant chemotherapy 5) No evidences of diseases at trial entry

Exclusion criteria

Exclusion criteria: 1) had a history of other active invasive malignancy in the past 5 years 2) Any reason the physician believes that the patient is not appropriate to participate in the study

Design outcomes

Primary

Measure	Time frame
Patient preferences for oral versus intravenous adjuvant chemotherapy for early breast cancer are assessed by questionnaires and evaluated the relationship of preference with various factors.	—

Countries

Japan

Contacts

Public ContactKazuyo Shibuya

Osaka Medical Center for Cancer and Cardiovascular Diseases Department of Breast and Endocrine Surgery

06-6972-1181

Outcome results